Ketorolac chemical structure
Find information on thousands of medical conditions and prescription drugs.

Toradol


Ketorolac or ketorolac tromethamine (marketed as Toradol® - generics have been approved) is a non-steroidal anti-inflammatory drug (NSAID) in the family of propionic acids, often used as an analgesic, antipyretic (fever reducer), and anti-inflammatory. Ketorolac acts by inhibiting bodily synthesis of prostaglandins. Ketorolac in its oral and intramuscular preparations is a racemic mixture of R-(+)(which is the salt 1H-Pyrrolizine-1-carboxylic acid,5-benzoyl-2,3-dihydro- ketorolac) and S-(-) (which does not have the 1H-Pyrrolizine-1-carboxylic acid,5-benzoyl-2,3-dihydro group) ketorolac. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

The brand name Toradol was coined by the Syntex company of the United States.

This article does not cover Acular® or ophthalmic ketorolac.

Chemistry

Ketorolac, like other 2-arylpropionate derivatives (including ketoprofen, flurbiprofen, naproxen, ibuprofen etc.) contains a chiral carbon in the β-position of the propionate moiety. As such there are two possible enantiomers of ketorolac with the potential for different biological effects and metabolism for each enantiomer.

NSAIDs are not recommended for use with other NSAIDs because of the potential for additive side effects.

The protein-binding effect of most non-aspirin NSAIDs is inhibited by the presence of aspirin in the blood.

Mechanism of action

The primary mechanism of action responsible for Ketorolac's anti-inflammatory/antipyretic/analgesic effects is the inhibition of prostaglandin synthesis by competitive blocking of the the enzyme cyclooxygenase (COX). Like most NSAIDs, Ketorolac is a non-selective cyclooxygenase inhibitor.

As with other NSAIDs, the mechanism of the drug is associated with the chiral S form. Conversion of the R enantiomer into the S enantiomer has been shown to occur in the metabolism of ibuprofen; it is unknown whether it occurs in the metabolism of ketorolac.

Image:Ketorolac bottles.jpg

Indications

Ketorolac is indicated for short-term management of pain (up to five days).

Contraindications

Ketorolac is contraindicated against patients with a previously demonstrated hypersensitivity to ketorolac, and against patients with the complete or partial syndrome of nasal polyps, angioedema, bronchospastic reactivity or other allergic manifestations to aspirin or other non-steroidal anti-inflammatory drugs (due to possibility of severe anaphylaxis).

Adverse effects

Similar to other NSAIDs. See inset "Ketorolac adverse effects."

Warnings and precautions

The most serious risks associated with ketorolac are, as with other NSAIDs, gastrointestinal ulcerations, bleeding and perforation; renal events ranging from interstitial nephritis to complete renal failure; hemorhage, and hypersensitivity reactions.

As with other NSAIDs, fluid and solute retention and edema have been reported with ketorolac; ketorolac elevated liver protein levels; it also inhibits platelet aggregation and may be associated with an increased risk of bleeding.

Notes

Ketorolac is not recommended for pre-operative analgesia or co-administration with anesthesia because it inhibits platelet aggregation.

Ketorolac is not recommended for obstetric analgesia because it has not been adequately tested for obstetrical administration and has demonstrable fetal toxicity in laboratory animals.

Read more at Wikipedia.org


[List your site here Free!]


Renal colic: NSAIDs more effective, less noxious than opioid analgesics
From Journal of Family Practice, 10/1/04 by A Holdgate

Holdgate A, Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ 2004; 328:1401-1404.

* CLINICAL QUESTION

Are intravenous nonsteroidal anti-inflammatory drugs (NSAIDs) more effective than narcotics for the treatment of patients with acute renal colic?

* BOTTOM LINE

NSAIDs produce equivalent or better analgesia than opioid narcotics, reduce the need for additional analgesia, and result in less vomiting among patients with renal colic. Not studied was a potential benefit of NSAIDs on the duration of colic; their ability to cause ureteral dilation may hasten stone passage. (LOE=1a)

* STUDY DESIGN

Meta-analysis (randomized controlled trials)

* SETTING

Various (meta-analysis)

* SYNOPSIS

The authors of this study scoured nephrology textbooks, review articles, study bibliographies, conference proceedings, and 4 databases to find the 20 trials that compared (usually) intravenous NSAIDs with opioids for a total of 1613 patients with acute renal colic. The authors didn't describe how this search was performed or how articles were selected for inclusion.

Of the 9 trials that evaluated pain at a fixed time after therapy was given, pain reports were slightly but significantly lower in the NSAID group. Studies with ketorolac (Toradol) produced heterogeneous results, but other NSAIDs produced scores that were lower, on average, by 4.6 mm on a 100-mm visual analog scale (a difference of 13 mm to 15 mm is considered clinically relevant).

The number of patients with complete pain relief at 30 or 60 minutes was similar in the 2 groups. However, the risk of patients requiring rescue (ie, additional) analgesia was significantly less in the NSAID group (relative risk=0.75; 95% confidence interval [CI], 0.61-0.93).

Approximately 16 patients treated with an NSAID instead of a narcotic (9 of 10 trials used meperidine [Demerol]) would need to be treated for 1 additional patient to avoid the need for additional analgesia (number needed to treat=16; 95% CI, 10-57).

Vomiting occurred less often with NSAIDs than with narcotic treatment (relative risk = 0.35; 95% CI, 0.23-0.53), with 1 fewer patient vomiting for every 8 patients treated with an NSAID instead of an opioid (95% CI, 7-11). Vomiting risk was highest with meperidine.

The effect of the type of analgesia on the duration of colic was not evaluated in these studies, although their pharmacology would suggest NSAIDs, by causing relaxation of the greeters, would produce more rapid resolution.

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Toradol
Home Contact Resources Exchange Links ebay